Antimicrobial effect of Casiopeinas® copper- and ruthenium-based compounds on Aggregatibacter actinomycetemcomitans and in vitro cell viability onto osteoblasts cells

Braz J Microbiol. 2022 Mar;53(1):179-184. doi: 10.1007/s42770-021-00648-3. Epub 2021 Nov 5.

Abstract

Objectives: The present study aims to evaluate the antimicrobial property of Casiopeinas® copper- and ruthenium-based compounds against Aggregatibacter actinomycetemcomitans serotype b (ATCC® 43,718™), as well as the cytotoxicity on an osteoblasts cell line of both compounds.

Material and methods: The antibacterial effect of the copper-based compounds (CasII-gly, CasIII-ia) and the ruthenium-based compound (RuN-6) at four different concentrations was evaluated as the inhibition ratio of the bacterial growth after 48 h under anaerobic conditions, and the cell viability was measured through resazurin assay.

Results: The copper- and ruthenium-based compounds used for this assay were (CasII-gly, CasIII-ia, and RuN-6), showing inhibitory activity between 39 and 62% compared to the antibiotic employed as control 66%. Cell viability was established between 61 and 96%.

Conclusions: Casiopeinas® and ruthenium showed dose and time dependent, inhibitory activity on A. actinomycetemcomitans, and low toxicity on cells (osteoblast) underexposure. The compound CasII-gly showed the best antimicrobial effect, and it could be considered a possible antimicrobial agent in periodontal therapy.

Keywords: Aggregatibacter actinomycetemcomitans; Antimicrobial effect; Casiopeinas®; Copper; Ruthenium.

MeSH terms

  • Aggregatibacter actinomycetemcomitans*
  • Cell Survival
  • Copper / pharmacology
  • Osteoblasts
  • Ruthenium Compounds / pharmacology
  • Ruthenium* / pharmacology

Substances

  • Ruthenium Compounds
  • Copper
  • Ruthenium